盐酸喹那普利（CAS 82586-55-8）：分子式 C25H31ClN2O5、分子量 475.0。
| CAS号 | 82586-55-8 |
|---|---|
| 分子式 | C25H31ClN2O5 |
| 分子量 | 475.0 |
| 应用领域 | Uses: Medication、For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.、Methods of Manufacturing: Preparation: M.L. Hoefle、S. Klutchko、EP 49605、eidem、US 4344949 (both 1982 to Warner-Lambert)...Synthesis of novel crystalline and purified form: O.P. Goel、U. Krolls、US 4761479 (1988 to Warner-Lambert)、Formulations、Preparations: CI-906、PD-109452-2、Accupril、Accuprin、Accupro、Acequin、Acuitel、Korec、Quinazil、Quinaprilat、Diacid of Quinapril、Acequide、Koretic、Mixture with Hydrochlorothiazide、The main ingredient in the drug Accupril ... (tablets)、General Manufacturing Information: The main ingredient in the drug Accuretic ... (tablets)、The major objective of this study was to investigate the effects of beta-cyclodextrin (beta-CD) & hydroxypropyl-beta-cyclodextrin (HP-beta-CD) on the solid-state chemical reactivity of the drug、quinapril、when amorphous samples are prepared by colyophilization of quinapril & each of these beta-CDs. For comparison、a physical mixture with beta-CD & colyophilized mixtures with trehalose & dextran were also prepared & subjected to a similar chemical stability test at 80 °C followed by HPLC analysis. Significant inhibition of degradation was observed only for colyophilized miscible mixtures with beta-CD & HP-beta-CD at molar ratios in excess of 1:1. Colyophilized mixtures with trehalose & dextran、shown to have phase separated、& the physical mixture with beta-CD exhibited no inhibiting effects. This suggests that specific molecular complexation is responsible for the significant inhibition by the beta-CDs. The tendency of quinapril to form molecular complexes in soln with the beta-CDs was measured by (1)H solution NMR、by estimating complexation constants from the chemical shift of specific groups on quinapril. Supporting evidence for solid-state complexation was provided by FTIR analysis. DSC & TSC measurements indicated that the beta-CDs do not have high enough glass transition temperatures to reduce reactivity by reducing molecular mobility. |
登记用途：Uses: Medication、For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.、Methods of Manufacturing: Preparation: M.L. Hoefle、S. Klutchko、EP 49605、eidem、US 4344949 (both 1982 to Warner-Lambert)...Synthesis of novel crystalline and purified form: O.P. Goel、U. Krolls、US 4761479 (1988 to Warner-Lambert)、Formulations、Preparations: CI-906、PD-109452-2、Accupril、Accuprin、Accupro、Acequin、Acuitel、Korec、Quinazil、Quinaprilat、Diacid of Quinapril、Acequide、Koretic、Mixture with Hydrochlorothiazide、The main ingredient in the drug Accupril ... (tablets)、General Manufacturing Information: The main ingredient in the drug Accuretic ... (tablets)、The major objective of this study was to investigate the effects of beta-cyclodextrin (beta-CD) & hydroxypropyl-beta-cyclodextrin (HP-beta-CD) on the solid-state chemical reactivity of the drug、quinapril、when amorphous samples are prepared by colyophilization of quinapril & each of these beta-CDs. For comparison、a physical mixture with beta-CD & colyophilized mixtures with trehalose & dextran were also prepared & subjected to a similar chemical stability test at 80 °C followed by HPLC analysis. Significant inhibition of degradation was observed only for colyophilized miscible mixtures with beta-CD & HP-beta-CD at molar ratios in excess of 1:1. Colyophilized mixtures with trehalose & dextran、shown to have phase separated、& the physical mixture with beta-CD exhibited no inhibiting effects. This suggests that specific molecular complexation is responsible for the significant inhibition by the beta-CDs. The tendency of quinapril to form molecular complexes in soln with the beta-CDs was measured by (1)H solution NMR、by estimating complexation constants from the chemical shift of specific groups on quinapril. Supporting evidence for solid-state complexation was provided by FTIR analysis. DSC & TSC measurements indicated that the beta-CDs do not have high enough glass transition temperatures to reduce reactivity by reducing molecular mobility.。
盐酸喹那普利 是一种化工化合物，登记 CAS 号为 82586-55-8，分子式 C25H31ClN2O5（分子量 475.0）。
登记 CAS 号：82586-55-8
其分子式 C25H31ClN2O5 由 25 个碳、31 个氢、1 个氯、2 个氮、5 个氧 组成。
别名/同义词：盐酸喹那普利 · Quinapril hydrochloride
盐酸喹那普利 的 CAS 登记号为 82586-55-8。
分子式 C25H31ClN2O5，分子量 475.0。
别名/同义词：盐酸喹那普利、Quinapril hydrochloride。
登记用途：Uses: Medication、For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.、Methods of Manufacturing: Preparation: M.L. Hoefle、S. Klutchko、EP 49605、eidem、US 4344949 (both 1982 to Warner-Lambert)...Synthesis of novel crystalline and purified form: O.P. Goel、U. Krolls、US 4761479 (1988 to Warner-Lambert)、Formulations、Preparations: CI-906、PD-109452-2、Accupril、Accuprin、Accupro、Acequin、Acuitel、Korec、Quinazil、Quinaprilat、Diacid of Quinapril、Acequide、Koretic、Mixture with Hydrochlorothiazide、The main ingredient in the drug Accupril ... (tablets)、General Manufacturing Information: The main ingredient in the drug Accuretic ... (tablets)、The major objective of this study was to investigate the effects of beta-cyclodextrin (beta-CD) & hydroxypropyl-beta-cyclodextrin (HP-beta-CD) on the solid-state chemical reactivity of the drug、quinapril、when amorphous samples are prepared by colyophilization of quinapril & each of these beta-CDs. For comparison、a physical mixture with beta-CD & colyophilized mixtures with trehalose & dextran were also prepared & subjected to a similar chemical stability test at 80 °C followed by HPLC analysis. Significant inhibition of degradation was observed only for colyophilized miscible mixtures with beta-CD & HP-beta-CD at molar ratios in excess of 1:1. Colyophilized mixtures with trehalose & dextran、shown to have phase separated、& the physical mixture with beta-CD exhibited no inhibiting effects. This suggests that specific molecular complexation is responsible for the significant inhibition by the beta-CDs. The tendency of quinapril to form molecular complexes in soln with the beta-CDs was measured by (1)H solution NMR、by estimating complexation constants from the chemical shift of specific groups on quinapril. Supporting evidence for solid-state complexation was provided by FTIR analysis. DSC & TSC measurements indicated that the beta-CDs do not have high enough glass transition temperatures to reduce reactivity by reducing molecular mobility.。
盐酸喹那普利（CAS 82586-55-8）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 82586-55-8 |
|---|---|
| PubChem CID | 54891 |
| Molecular formula | C25H31ClN2O5 |
| IUPAC name | (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;hydrochloride |
| UNII (FDA) | 33067B3N2M |
| Molecular Weight | 475.0 |
|---|---|
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 10 |
| Exact Mass | 474.1921498 |
| Monoisotopic Mass | 474.1921498 |
| Topological Polar Surface Area | 95.9 |
| Heavy Atom Count | 33 |
QUINAPRIL HYDROCHLORIDE; 82586-55-8; QUINAPRIL HCL; Korec; Accuprin; Quinazil; Acequin; Acuitel; Hemokvin; Accupro; CI-906; DTXSID3021221; CI 906; NSC-758222; 33067B3N2M; CHEBI:8714
| Reported hazard statements | H361 (53%) |
|---|
H361 (53%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
H361d (43.9%): Suspected of damaging the unborn child [Warning Reproductive toxicity]
Quinapril hydrochloride · CAS 82586-55-8 · C25H31ClN2O5. UNII 33067B3N2M.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Quinapril hydrochloride